How to Reconstitute BPC-157 for Travel and Transport Without Losing Potency

What Is BPC-157 and Why Does Reconstitution Matter?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence found in human gastric juice. It is supplied as a lyophilized (freeze-dried) white powder precisely because the peptide degrades rapidly in aqueous solution at room temperature. Reconstitution converts that powder into an injectable solution, and every step you take from that moment forward either preserves or destroys the peptide's activity.

For women specifically, BPC-157 is being explored for tissue repair after pelvic floor injury, tendon healing following postpartum musculoskeletal strain, and gut-lining support in conditions like endometriosis-related gastrointestinal inflammation. None of these uses carry FDA approval. BPC-157 is not an FDA-approved drug. It is available only through compounding pharmacies or research suppliers, and its legal status for human use remains unsettled.

Because reconstituted peptide solutions are fragile, women who travel for work, attend conferences, or manage split-household schedules need a practical system that keeps BPC-157 viable across time zones, varying climates, and airport security checks.

The Science Behind Peptide Stability

Peptide degradation follows predictable chemistry. Understanding it helps you make smarter packing decisions.

Why Lyophilized Powder Is Stable but Reconstituted Solution Is Not

Lyophilized BPC-157 powder stored at -20°C remains stable for 12-24 months in an unopened vial because removing water halts hydrolysis, oxidation, and microbial growth. Once you add bacteriostatic water, you restart the clock. Peptide hydrolysis rates roughly double for every 10°C rise in temperature, which is why a vial left in a hot car for two hours may look identical but perform very differently.

Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of a reconstituted solution to approximately 28 days refrigerated. Sterile water for injection, by contrast, carries no preservative and should be used within 24 hours once opened. This distinction matters enormously when you are traveling and cannot guarantee same-day use.

What Damages Reconstituted BPC-157

Three enemies account for almost all potency loss in transit:

• Heat. Above 25°C, peptide bond hydrolysis accelerates. At sustained temperatures above 37°C, measurable degradation occurs within hours.
• Light. UV exposure generates free radicals that cleave peptide bonds. Amber glass vials exist for a reason.
• Agitation. Shaking a peptide solution causes surface denaturation at the air-liquid interface. Protein and peptide aggregation from mechanical stress is well-documented in pharmaceutical formulation literature.

Step-by-Step: How to Reconstitute BPC-157

Gather everything before you open anything. Contamination introduced during reconstitution cannot be reversed.

What You Need

• BPC-157 lyophilized powder vial (5 mg is standard)
• Bacteriostatic water for injection (10 mL multi-dose vial)
• 18-21 gauge drawing needle for reconstitution (blunt-tip cannula preferred)
• 29-31 gauge insulin syringes for injection (0.5 mL or 1 mL)
• Isopropyl alcohol swabs (70%)
• Sharps disposal container
• Permanent marker for date-labeling

The Reconstitution Protocol

Step 1. Clean your workspace. Wipe the surface with a fresh alcohol swab. Wash hands for 20 seconds.

Step 2. Swab both stoppers. Clean the rubber stopper on the BPC-157 vial and the bacteriostatic water vial with separate swabs. Let both air-dry for 10 seconds. Do not blow on them or fan them dry.

Step 3. Draw bacteriostatic water. Insert the drawing needle into the bacteriostatic water vial. Withdraw the volume you need (see dosing calculator section below). For a 5 mg vial, most practitioners use 2.0-2.5 mL of bacteriostatic water.

Step 4. Inject slowly along the glass wall. Insert the needle into the BPC-157 vial and direct the stream of bacteriostatic water down the inside glass wall, not directly onto the powder cake. This prevents foaming and mechanical peptide damage.

Step 5. Swirl, do not shake. Gently rotate the vial between your fingers for 15-20 seconds until the powder dissolves completely. The solution should be clear and colorless. Cloudiness or particulate matter means discard.

Step 6. Label immediately. Write the reconstitution date and the resulting concentration on the vial. Set a phone reminder for 28 days.

Step 7. Refrigerate at 2-8°C within 30 minutes if you are not drawing your first dose immediately.

BPC-157 Dosing Calculator: Working Out Your Concentration and Draw Volume

This is the section most guides skip or get wrong. Getting the math right before travel means you can pre-draw syringes accurately without recalculating under pressure.

The Core Formula

Concentration (mcg/mL) = Total peptide (mcg) / Bacteriostatic water volume (mL)

A 5 mg vial contains 5,000 mcg of BPC-157.

| Bacteriostatic Water Added | Resulting Concentration | Volume to draw for 250 mcg dose | Volume to draw for 500 mcg dose | |---|---|---|---| | 1.0 mL | 5,000 mcg/mL | 0.05 mL (5 units on U-100 syringe) | 0.10 mL (10 units) | | 2.0 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) | | 2.5 mL | 2,000 mcg/mL | 0.125 mL (12.5 units) | 0.25 mL (25 units) | | 5.0 mL | 1,000 mcg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) |

The 2.5 mL reconstitution (yielding 2,000 mcg/mL) is the most practical for women using standard insulin syringes because the draw volumes fall on readable syringe markings and avoid sub-0.1 mL doses that are hard to measure accurately.

Reading an Insulin Syringe Correctly

A standard U-100 insulin syringe marks each unit as 0.01 mL. So 10 units = 0.10 mL, 25 units = 0.25 mL, and 50 units = 0.50 mL. If your clinician prescribes a dose in micrograms, divide by your concentration to get milliliters, then multiply by 100 to get units on the syringe.

Example: You are prescribed 250 mcg. Your vial is at 2,000 mcg/mL.

• 250 mcg / 2,000 mcg/mL = 0.125 mL
• 0.125 mL × 100 = 12.5 units on the syringe

A 29-gauge, half-inch needle on a 0.5 mL syringe is the standard for subcutaneous injection into the lower abdomen, outer thigh, or flank. Subcutaneous needle length recommendations of 4-8 mm are supported by injection technique literature across multiple peptide and insulin studies.

How to Travel With Reconstituted BPC-157 Without Losing Potency

Travel is where most peptide potency loss happens. This section gives you a tested system.

Pre-Travel Preparation: The 48-Hour Window

Reconstitute your vial no more than 48 hours before departure. This preserves maximum peptide integrity for the full travel period ahead while still giving you a stable solution. If you are traveling for more than 3 weeks, consider carrying lyophilized powder (stable at -20°C) in a dry-ice shipper and reconstituting at your destination.

Pre-draw individual doses into insulin syringes if your trip is 7 days or fewer. Capped pre-drawn syringes stored at 2-8°C remain stable for up to 7 days in the barrel of a polypropylene syringe. Polypropylene syringes show minimal peptide adsorption compared to glass when storage is brief. Label each syringe with the date drawn and the dose.

What to Pack

• Insulated medication travel case with a reusable gel pack (not loose ice, which creates moisture). Frio Wallet-style evaporative cases maintain 18-26°C, acceptable for up to 24 hours of transit, but refrigeration is still preferred.
• Amber-glass or opaque-capped vial to block UV exposure.
• Sharps container (TSA-compliant, under 1-quart size).
• Prescriber letter on clinic letterhead stating the medication name, dose, and your name. This is not legally required for domestic US travel but prevents unnecessary TSA delays.
• Alcohol swabs and gloves in your carry-on.

Airport Security and Carry-On Rules

The TSA explicitly permits injectable medications and their associated supplies in carry-on bags and does not require a prescription label, though one is recommended. Declare your injectable medications at the screening checkpoint before the bin goes through the X-ray. Ask for a hand inspection of temperature-sensitive medications; X-ray exposure at standard airport scanner doses has not been shown to degrade peptides, but avoiding unnecessary exposure is reasonable practice.

Never pack your reconstituted BPC-157 in checked luggage. Cargo holds can reach -40°C or above 55°C during flight, both of which are destructive to reconstituted peptides.

Managing Temperature During Long Travel Days

On travel days longer than 12 hours:

• Request ice from airport food vendors to refresh gel packs during layovers.
• At hotel check-in, ask for a mini-fridge in your room and place the vial at the back (coldest zone), not the door.
• If a mini-fridge is unavailable, a hotel ice bucket with crushed ice and a zip-lock barrier around the vial maintains adequate temperature for 6-8 hours.
• Never freeze a reconstituted solution; ice crystal formation disrupts the peptide structure. Freeze-thaw cycling of peptide solutions produces aggregation and loss of biological activity in formulation studies.

International Travel Considerations

BPC-157 legal status varies by country. Several countries classify unlicensed peptides as controlled or prescription-only substances. Before traveling internationally:

• Verify the legal status in your destination country through that country's regulatory authority.
• Carry a maximum 90-day supply for personal use (the general customs standard, though not universal).
• Travel with a prescriber letter translated into the destination language where practical.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

BPC-157 is not safe to use during pregnancy. This is the most important statement in this article for reproductive-age women.

Pregnancy

No human safety data exist for BPC-157 in pregnancy. Animal studies examining BPC-157 in rodent models have not been designed to assess embryotoxicity specifically, which means absence of evidence is not evidence of absence. The FDA's position on compounded peptides states they are not evaluated for safety or efficacy and should not be assumed safe in pregnancy. Because BPC-157 is an unapproved compound with no pregnancy category assignment, the only clinically reasonable position is to treat it as contraindicated in pregnancy.

If you are trying to conceive, discuss with your OB-GYN or reproductive endocrinologist before starting BPC-157. The drug's half-life in subcutaneous injection models is estimated at under 4 hours, but clearance data in women is essentially nonexistent.

Lactation

No data exist on BPC-157 transfer into human breast milk. Peptides are generally degraded in the infant gut, which might limit systemic absorption, but this reasoning is extrapolated from pharmacokinetics of other short peptides, not from BPC-157-specific lactation studies. Until data exist, the conservative and appropriate recommendation is to avoid BPC-157 while breastfeeding.

Contraception Requirement

Women of reproductive age using BPC-157 should use reliable contraception throughout the course of use. A barrier method plus a hormonal method offers the most reliable protection for women who do not wish to become pregnant while using any unapproved peptide compound.

PCOS, Endometriosis, and Perimenopause Context

Women with PCOS or endometriosis are among the groups most likely to seek BPC-157 for gut motility support and tissue repair. No condition-specific dosing data exist for these populations. Women in perimenopause exploring BPC-157 for tendon and joint recovery should know that estrogen decline already impairs collagen synthesis, as documented in multiple musculoskeletal studies in perimenopausal women. BPC-157's proposed mechanism of upregulating growth hormone receptor expression and stimulating tendon fibroblasts may theoretically complement this gap, but that remains speculative. Clinical trial data in women with these conditions are absent.

Who This Is Right For (and Who Should Avoid It)

Women Who May Be Candidates

• Postpartum women (not breastfeeding) with pelvic floor or musculoskeletal injury seeking adjunct tissue repair support under clinical supervision.
• Perimenopausal or postmenopausal women with tendinopathy or gut-motility issues who have discussed peptide use with a qualified clinician.
• Women with endometriosis-related gastrointestinal symptoms working with a practitioner who has specific peptide prescribing experience.

In all cases, BPC-157 should be prescribed or supervised by a licensed clinician, not self-administered from a research supplier.

Women Who Should Avoid BPC-157

• Anyone who is pregnant or planning pregnancy within the next 3 months.
• Breastfeeding women.
• Women with a personal or family history of hormone-sensitive tumors, given the lack of safety data on growth-factor-adjacent compounds in this population.
• Women with active infections, as BPC-157's proposed angiogenic effects are theoretically unfavorable in the setting of infection.
• Women taking anticoagulants, as BPC-157 has shown platelet-modulating effects in animal models.

How to Know If Your BPC-157 Has Degraded

You cannot always tell by looking. A degraded solution may still appear clear. However, these are signs to discard immediately:

• Cloudiness, particulate matter, or visible precipitate.
• Pink or yellow color change (should be colorless).
• Solution was left above 30°C for more than 60 minutes.
• More than 28 days since reconstitution.
• The vial was accidentally frozen and thawed.

When in doubt, discard. The cost of a replacement vial is lower than the risk of injecting a degraded or potentially contaminated compound. USP general chapter <797> on pharmaceutical compounding sets beyond-use dates for sterile preparations based on risk level and storage conditions, and a reconstituted peptide vial stored in a home refrigerator falls into a category requiring conservative dating.

Injection Technique for Subcutaneous Administration

Once you have your pre-drawn syringe and have verified the solution is clear, colorless, and within the use window:

1. Choose a site: lower abdomen (at least 2 inches from the navel), outer thigh, or flank. Rotate sites with each injection to prevent lipohypertrophy.
2. Clean the site with an alcohol swab and let it air-dry for 10 seconds.
3. Pinch a fold of skin gently.
4. Insert the needle at a 45-degree angle for subcutaneous injection (90 degrees if using a 4 mm pen needle or if injecting into thicker tissue).
5. Inject slowly over 5-10 seconds.
6. Withdraw the needle and apply gentle pressure with a dry swab. Do not rub.
7. Dispose of the needle immediately in your sharps container.

Subcutaneous injection technique guidelines from the American Diabetes Association recommend site rotation and a consistent angle to minimize tissue trauma and variability in absorption.